香雪製藥(300147.SZ)子公司擬劃轉名下貨幣資金等資產及九極保健100%股權
格隆匯12月31日丨香雪製藥(300147.SZ)公佈,為進一步優化整合公司內部資源,提升公司資產配置及業務的專業化管理,公司下屬全資子公司廣東九極生物科技有限公司(“九極生物”)將名下的貨幣資金、固定資產、無形資產等相關資產按審計後的賬面淨資產值無償劃轉至公司全資子公司廣州芮培優生優育醫療有限公司。同時,將下屬全資子公司廣東九極日用保健品有限公司(“九極保健”)100%股權按審計後的賬面值無償劃轉至公司全資子公司廣州香雪健康產業股權投資管理有限公司。
(一)資產劃轉協議
甲方(劃出方):廣東九極生物科技有限公司;乙方(劃入方):廣州芮培優生優育醫療有限公司
甲方為經營需要,願意根據本協議約定的條件和方式,在履行甲方內部必要審批程序的前提下,以賬面價值將本協議約定的相關資產劃轉給乙方,乙方同意接受甲方的劃轉。甲方擁有劃轉標的的所有權,截至2019年11月30日,本公司擬將九極生物劃轉至芮培醫療的資產總計約621.48萬元。
(二)股權劃轉協議
甲方(劃出方):廣東九極生物科技有限公司;乙方(劃入方):廣州香雪健康產業股權投資管理有限公司
甲方為公司經營需要,願意根據本協議約定的條件和方式,在履行甲方內部必要審批程序的前提下,將廣東九極日用保健品有限公司100%的股權劃轉給乙方,乙方同意接受甲方劃轉的股權。
此次資產劃轉和股權劃轉有利於優化資源配置,提高運營效率,有利於公司整體業績提升。此次交易完成後,公司合併報表範圍未發生變化,對公司的正常經營、財務狀況和經營成果不產生重大影響,不存在損害公司及股東利益的情形。公司將根據上述事項的進展情況,及時履行信息披露義務,敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.